Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    CBRNE

    DoD Seeks to Develop Advanced Anticholinergic with Increased Efficacy Against Nerve Agents

    By Global Biodefense StaffNovember 27, 2017
    Improved Nerve Agent Treatment System (INATS)
    Image: US Army Acquisition Support Center
    Share
    Facebook LinkedIn Reddit Email

    Therapeutic pharmaceuticals against chemical, biological, radiological and nuclear (CBRN) warfare agents are required to support the Joint Forces across a range of military operations. As such, the U.S. Department of Defense (DoD) has a need for developing and fielding systems that provide treatment for exposure to CBRN agents.

    The DoD is repurposing scopolamine hydrobromide trihydrate as a centrally-acting adjunct therapy that would be administered in conjunction with the Antidote Treatment – Nerve Agent, Auto-Injector (ATNAA) upon exposure of an individual to a nerve agent.

    Scopolamine readily crosses the blood-brain barrier and acts as a competitive antagonist at muscarinic acetylcholine receptors. It is intended to improve survivability and medical treatment outcomes against the central symptoms of current and emerging nerve agent threats.

    If the Improved Nerve Agent Treatment System (INATS) – Scopolamine effort is successful, scopolamine will supplement existing medical countermeasures in a single chambered autoinjector similar to the Atropen.

    One objective of the INATS is to develop an improved nerve agent treatment regimen consisting of a centrally-acting anticholinergic to treat the central symptoms of nerve agent poisoning.

    This development effort requires the repurposing of scopolamine to include but not limited to:

    • Formulation, stability and compatibility studies
    • Non-clinical and clinical studies
    • Manufacturing process development
    • Large-scale manufacturing
    • Preparation and submission of a New Drug Application (NDA)

    A Request for Information (RFI) has been issued for the INATS effort by the Joint Product Manager for Chemical Defense Pharmaceuticals (JPdM CDP) at the Joint Program Executive Office for Chemical and Biological Defense (JPEO CBD) Medical Countermeasures Systems (MCS).

    All capable providers, particularly members of the CBRN Medical Countermeasures Defense Consortium are encouraged to respond. Respondents not already members of the consortium are encouraged to join at www.medcbrn.org.

    All written responses must be received by 30 November 2017 11:59 pm Eastern. Further details are available at FedBizOpps Solicitation Number: W15QKN-18-X-00O0.

    Chemical Weapons JPEO-CBRND RFI
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleExclusive Interviews: Tackling Regulatory and Economic Challenges of Antimicrobial Resistance
    Next Article PRISM: Advancing Nucleic Acid Vaccine Platform Technologies

    Related Stories

    Jurata Thin Film and CastleVax Awarded Grant to Advance Thermostabilized COVID-19 Booster

    September 20, 2023

    Terrorism and the Pandemic: Weaponizing a Public Health Crisis

    September 20, 2023

    SOREX Brings Top CBRNE Units to Dugway Proving Ground

    September 20, 2023

    Biomarkers for Detection of Exposure to Nitrogen Mustards

    September 20, 2023
    News Scan

    Biodefense Headlines – 19 September 2023

    News Scan September 19, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include a global survey of gain-of-function research; funding of an mRNA mpox vaccine; Nipah virus outbreak in India; field detection of threat agents with acoustic…

    Upcoming Events

    Oct 3
    Virtual Event Virtual Event
    October 3 - October 5

    OneLab Summit 2023

    Oct 3
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships to Distribute, Dispense, and Administer Medical Countermeasures

    Oct 4
    Virtual Event Virtual Event
    10:00 am - 2:00 pm EDT

    Tunneling Nanotubes and Intracellular Protrusions Workshop

    Oct 12
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships for Acceptance and Uptake of Medical Countermeasures

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.

    We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are okay with it.OkPrivacy policy